Nature Communications (Jun 2021)
BRN2 is a non-canonical melanoma tumor-suppressor
- Michael Hamm,
- Pierre Sohier,
- Valérie Petit,
- Jérémy H. Raymond,
- Véronique Delmas,
- Madeleine Le Coz,
- Franck Gesbert,
- Colin Kenny,
- Zackie Aktary,
- Marie Pouteaux,
- Florian Rambow,
- Alain Sarasin,
- Nisamanee Charoenchon,
- Alfonso Bellacosa,
- Luis Sanchez-del-Campo,
- Laura Mosteo,
- Martin Lauss,
- Dies Meijer,
- Eirikur Steingrimsson,
- Göran B. Jönsson,
- Robert A. Cornell,
- Irwin Davidson,
- Colin R. Goding,
- Lionel Larue
Affiliations
- Michael Hamm
- Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Normal and Pathological Development of Melanocytes
- Pierre Sohier
- Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Normal and Pathological Development of Melanocytes
- Valérie Petit
- Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Normal and Pathological Development of Melanocytes
- Jérémy H. Raymond
- Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Normal and Pathological Development of Melanocytes
- Véronique Delmas
- Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Normal and Pathological Development of Melanocytes
- Madeleine Le Coz
- Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Normal and Pathological Development of Melanocytes
- Franck Gesbert
- Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Normal and Pathological Development of Melanocytes
- Colin Kenny
- Department of Anatomy and Cell biology, Carver College of Medicine, University of Iowa
- Zackie Aktary
- Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Normal and Pathological Development of Melanocytes
- Marie Pouteaux
- Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Normal and Pathological Development of Melanocytes
- Florian Rambow
- Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Normal and Pathological Development of Melanocytes
- Alain Sarasin
- Laboratory of Genetic Instability and Oncogenesis, UMR8200 CNRS, Gustave Roussy, Université Paris-Sud
- Nisamanee Charoenchon
- Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Normal and Pathological Development of Melanocytes
- Alfonso Bellacosa
- Cancer Epigenetics Program, Fox Chase Cancer Center
- Luis Sanchez-del-Campo
- Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Headington
- Laura Mosteo
- Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Headington
- Martin Lauss
- Department of Oncology, Clinical Sciences Lund, Lund University and Skåne University Hospital
- Dies Meijer
- Centre of Neuroregeneration, University of Edinburgh
- Eirikur Steingrimsson
- Department of Biochemistry and Molecular Biology, and Department of Anatomy, BioMedical Center, Faculty of Medicine, University of Iceland
- Göran B. Jönsson
- Department of Oncology, Clinical Sciences Lund, Lund University and Skåne University Hospital
- Robert A. Cornell
- Department of Anatomy and Cell biology, Carver College of Medicine, University of Iowa
- Irwin Davidson
- Department of Anatomy and Cell biology, Carver College of Medicine, University of Iowa
- Colin R. Goding
- Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Headington
- Lionel Larue
- Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Normal and Pathological Development of Melanocytes
- DOI
- https://doi.org/10.1038/s41467-021-23973-5
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 16
Abstract
The transcription factor BRN2 regulates melanoma migration and invasion, but its role during melanoma initiation is unclear. Here the authors show that BRN2 is a haplo-insufficient tumour suppressor that positively regulates PTEN expression and in the context of BRAF mutation and heterozygous PTEN, BRN2 loss promotes melanoma initiation and progression.
